119 related articles for article (PubMed ID: 6869037)
1. Interactions of a partial ergoline with dopamine receptors in vivo and in vitro.
Fuxe K; Goldstein M; Agnati LF; Köhler C; Lew JY; Okada K
Acta Physiol Scand; 1983 Feb; 117(2):303-5. PubMed ID: 6869037
[No Abstract] [Full Text] [Related]
2. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding.
Sibley DR; Weinberger S; Segal DS; Creese I
Experientia; 1982 Oct; 38(10):1224-5. PubMed ID: 6890464
[No Abstract] [Full Text] [Related]
3. Selective modulation of 3H-spiperone labeled 5-HT receptors by subchronic treatment with the ganglioside GM1 in the rat.
Agnati LF; Benfenati F; Battistini N; Cavicchioli L; Fuxe K; Toffano G
Acta Physiol Scand; 1983 Feb; 117(2):311-4. PubMed ID: 6869038
[No Abstract] [Full Text] [Related]
4. Aging brain and dopamine receptors: abnormal regulation by CCK-8 of 3H-spiperone labeled dopamine receptors in striatal membranes.
Agnati LF; Fuxe K; Battistini N; Benfenati F
Acta Physiol Scand; 1984 Mar; 120(3):465-7. PubMed ID: 6331074
[No Abstract] [Full Text] [Related]
5. Occupation of dopamine receptors by N-n-propylnorapomorphine or spiperone and acetylcholine levels in the rat striatum.
Korf J; Sebens JB; Flentge F; van der Werf JF
J Neurochem; 1985 Jan; 44(1):314-8. PubMed ID: 3964835
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites.
Agnati LF; Celani MF; Fuxe K
Acta Physiol Scand; 1983 May; 118(1):79-81. PubMed ID: 6312748
[No Abstract] [Full Text] [Related]
7. Chronic dihydroergotoxine treatment affects the number of dopamine recognition sites in rat striatum.
Battaini F; Govoni S; Rius RA; Spano PF; Trabucchi M
Pharmacol Res Commun; 1984 Jun; 16(6):605-11. PubMed ID: 6463097
[TBL] [Abstract][Full Text] [Related]
8. Are striatal [3H]spiperone radioreceptor assays indicative of multiple dopamine receptor interactions?
Clements-Jewery S; Robson PA
Neuropharmacology; 1981 Dec; 20(12B):1295-8. PubMed ID: 7322304
[No Abstract] [Full Text] [Related]
9. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
Gundlach AL; Krstich M; Beart PM
Brain Res; 1983 Nov; 278(1-2):155-63. PubMed ID: 6227373
[TBL] [Abstract][Full Text] [Related]
10. Striatal dopamine receptor function in morphine-tolerant dependent rats: influence of hypothalamic peptides.
Bhargava HN
NIDA Res Monogr; 1984 Mar; 49():320-6. PubMed ID: 6148693
[No Abstract] [Full Text] [Related]
11. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
Hall MD; Jenner P; Kelly E; Marsden CD
Br J Pharmacol; 1983 Jun; 79(2):599-610. PubMed ID: 6418246
[TBL] [Abstract][Full Text] [Related]
12. On the mechanism of mergocryptine-induced suppression of dopamine turnover in the rat striatum.
Hashimoto T; Katsura M; Kuriyama K
Eur J Pharmacol; 1991 Jun; 198(2-3):121-7. PubMed ID: 1864302
[TBL] [Abstract][Full Text] [Related]
13. Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration.
Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2973-7. PubMed ID: 6626267
[TBL] [Abstract][Full Text] [Related]
14. Activation of accumbal and striatal dopamine autoreceptors by some ergoline derivatives.
Gundlach AL; Christie MJ; Beart PM
Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):149-52. PubMed ID: 3992029
[TBL] [Abstract][Full Text] [Related]
15. Optimal conditions for [3H]apomorphine binding and anomalous equilibrium binding of [3H]apomorphine and [3H]spiperone to rat striatal membranes: involvement of surface phenomena versus multiple binding sites.
Leysen JE; Gommeren W
J Neurochem; 1981 Jan; 36(1):201-19. PubMed ID: 7463046
[TBL] [Abstract][Full Text] [Related]
16. Lisuride inhibits 3H-spiroperidol binding to membranes isolated from striatum.
Fujita N; Saito K; Yonehara N; Yoshida H
Neuropharmacology; 1978 Dec; 17(12):1089-91. PubMed ID: 745698
[No Abstract] [Full Text] [Related]
17. The effect of melanotropin release inhibiting factor, its metabolites and analogs on [3H]spiroperidol and [3H]apomorphine binding sites.
Bhargava HN
Gen Pharmacol; 1983; 14(6):609-14. PubMed ID: 6141122
[TBL] [Abstract][Full Text] [Related]
18. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
Martin GE; Williams M; Haubrich DR
J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
[No Abstract] [Full Text] [Related]
19. Study on some compensatory responses of dopaminergic system in aging rats.
Algeri S; Achilli G; Cimino M; Perego C; Ponzio F; Vantini G
Exp Brain Res; 1982; Suppl 5():146-52. PubMed ID: 7151906
[No Abstract] [Full Text] [Related]
20. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
